Science Explorer Back to mapMap
Discussion
Company · Halle · Germany

Probiodrug (Germany)

probiodrug.deROR OpenAlex
Research works
100
▼ 88% vs 2018-21
Citations
4.3k
43.6 per fractional work
Top-10% rate
8.0%
all institutions 10.0%
Open access
33%
world 40%
International
32%
world 18%
Probiodrug (Germany)

Not ranked overall: Probiodrug (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Probiodrug (Germany) work in?

In all years, 54% of research at Probiodrug (Germany) is in Life Sciences, 37% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (37%), Medicine (36%), Neuroscience (14%). It does 3.2× the world's share of Life Sciences.

Life Sciences: 54 fractional works · 53.9% of its workBiochemistry, Genetics and Molecular Biology: 37 fractional works · 36.8% of its workMolecular Biology: 23 fractional works · 22.6% of its workBiochemistry: 8 fractional works · 8.2% of its workCell Biology: 2 fractional works · 2.3% of its workCancer Research: 2 fractional works · 2.2% of its workClinical Biochemistry: 1 fractional works · 0.6% of its workBiotechnology: 0 fractional works · 0.5% of its workGenetics: 0 fractional works · 0.3% of its workNeuroscience: 14 fractional works · 13.6% of its workCellular and Molecular Neuroscience: 11 fractional works · 10.9% of its workBiological Psychiatry: 1 fractional works · 1.5% of its workCognitive Neuroscience: 0 fractional works · 0.5% of its workEndocrine and Autonomic Systems: 0 fractional works · 0.3% of its workNeurology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workImmunology and Microbiology: 2 fractional works · 2.0% of its workImmunology: 2 fractional works · 1.9% of its workSmaller subfields together: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 1 fractional works · 1.3% of its workPlant Science: 0 fractional works · 0.5% of its workFood Science: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.3% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.2% of its workHealth Sciences: 36 fractional works · 36.5% of its workMedicine: 36 fractional works · 36.1% of its workOncology: 13 fractional works · 13.4% of its workPhysiology: 10 fractional works · 10.0% of its workEndocrinology, Diabetes and Metabolism: 6 fractional works · 6.0% of its workSurgery: 2 fractional works · 1.8% of its workPathology and Forensic Medicine: 1 fractional works · 0.6% of its workPharmacology: 1 fractional works · 0.6% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 0.5% of its workPsychiatry and Mental health: 0 fractional works · 0.4% of its workRheumatology: 0 fractional works · 0.4% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.4% of its workEpidemiology: 0 fractional works · 0.4% of its workImmunology and Allergy: 0 fractional works · 0.3% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.3% of its workInfectious Diseases: 0 fractional works · 0.3% of its workSmaller subfields together: 1 fractional works · 0.7% of its workHealth Professions: 0 fractional works · 0.4% of its workPharmacy: 0 fractional works · 0.4% of its workPhysical Sciences: 9 fractional works · 9.5% of its workChemistry: 4 fractional works · 4.4% of its workOrganic Chemistry: 3 fractional works · 2.8% of its workSpectroscopy: 1 fractional works · 1.0% of its workAnalytical Chemistry: 0 fractional works · 0.3% of its workPhysical and Theoretical Chemistry: 0 fractional works · 0.3% of its workMaterials Science: 2 fractional works · 2.4% of its workMaterials Chemistry: 2 fractional works · 1.8% of its workBiomaterials: 1 fractional works · 0.6% of its workEngineering: 1 fractional works · 0.9% of its workMechanical Engineering: 0 fractional works · 0.5% of its workBiomedical Engineering: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workComputer Science: 1 fractional works · 0.8% of its workComputational Theory and Mathematics: 1 fractional works · 0.8% of its workEnvironmental Science: 0 fractional works · 0.5% of its workPhysics and Astronomy: 0 fractional works · 0.4% of its workAtomic and Molecular Physics, and Optics: 0 fractional works · 0.4% of its workSocial Sciences: 0 fractional works · 0.1% of its workPsychology: 0 fractional works · 0.1% of its workALL ITS WORKProbiodrug(Germany)100fractional works, all years
Life Sciences54%Physical Sciences9%Health Sciences37%Social Sciences0%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 14 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology3736.8%
    2. Neuroscience1413.6%
    3. Immunology and Microbiology22.0%
    4. Agricultural and Biological Sciences11.3%
    5. Pharmacology, Toxicology and Pharmaceutics00.2%
    1. Medicine3636.1%
    2. Health Professions00.4%
    1. Chemistry44.4%
    2. Materials Science22.4%
    3. Engineering10.9%
    4. Computer Science10.8%
    5. Environmental Science00.5%
    6. Physics and Astronomy00.4%
    1. Psychology00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What does Probiodrug (Germany) specialise in?

Where its research is concentrated relative to its size: Molecular Biology takes 5.7× the share of its output that it takes of world research.

  1. Molecular BiologySubfield · 22.5 works5.7×
← less than its size predicts1×more →

Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Probiodrug (Germany)?

Ranked on the quality score, Stephan Schilling, Hans‐Ulrich Demuth and Martin Kleinschmidt lead among researchers whose main affiliation is Probiodrug (Germany).

  1. 1 Stephan Schilling Germany · #968,162 worldwide 4.7k citations · 93 works
  2. 2 Hans‐Ulrich Demuth Germany · #1,153,078 worldwide 4.1k citations · 88 works
  3. 3 Martin Kleinschmidt Germany · #1,300,158 worldwide 1.6k citations · 35 works
  4. 4 Birgit Maria Koch Germany · #1,449,847 worldwide 4.2k citations · 87 works
  5. 5 Susanne Manhart Germany · #1,523,373 worldwide 1.9k citations · 37 works
  6. 6 Hans‐Ulrich Demuth Germany · #1,716,226 worldwide 5.5k citations · 144 works
  7. 7 Hans-Ulrich Demuth Germany · #1,902,479 worldwide 1k citations · 15 works
  8. 8 Torsten Hoffmann Germany · #1,972,087 worldwide 8.1k citations · 197 works
  9. 9 Leona Wagner Germany · #2,351,584 worldwide 1.8k citations · 56 works
  10. 10 Michael Wermann Germany · #2,396,550 worldwide 1.5k citations · 38 works
All ranked researchers at Probiodrug (Germany)

What are the most cited papers from Probiodrug (Germany)?

The most cited paper from Probiodrug (Germany) is "Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β" (Justin M. Nussbaum, Stephan Schilling, Holger Cynis et al., 2012), with 437 citations. Next come "Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology" (357) and "Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats" (334).

Most cited papers
#PaperReleasedCitations
1 Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β Justin M. Nussbaum, Stephan Schilling, Holger Cynis et al. · Nature Open access May 2012 437
2 Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology Stephan Schilling, Ulrike Zeitschel, Torsten Hoffmann et al. · Nature Medicine 28 Sep 2008 357
3 Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats John Andrew Pospisilik, Jennifer Martin, Timothy Doty et al. · Diabetes Open access Mar 2003 334
4 The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism Michael H. Engel, Torsten Hoffmann, Leona Wagner et al. · Proceedings of the National Academy of Sciences Open access 10 Apr 2003 307
5 On the Seeding and Oligomerization of pGlu-Amyloid Peptides (in vitro) Stephan Schilling, Thomas Lauber, Michael Schaupp et al. · Biochemistry 20 Sep 2006 259
All 61 most cited papers, with filters and sorting

Which keywords describe research at Probiodrug (Germany)?

By fractional works in all years, weighted toward what it does more of than the world: Oxidative Stress, Angiogenesis, Cancer, Tumor Microenvironment, Cancer Therapy, Immunosuppression, PET Imaging and Fibroblast Activation Protein.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Oxidative Stress15▲ 8.3×12 topics
  2. Angiogenesis15▲ 37×7 topics
  3. Cancer13▲ 9.6×12 topics
  4. Tumor Microenvironment12▲ 35×5 topics
  5. Cancer Therapy12▲ 20×4 topics
  6. Immunosuppression12▲ 101×2 topics
  7. PET Imaging12▲ 54×2 topics
  8. Fibroblast Activation Protein12▲ 225×1 topic
  9. N-terminal Acetylation12▲ 225×1 topic
  10. Neuroinflammation11▲ 41×4 topics
  11. Depression10▲ 14×3 topics
  12. Neurodegeneration10▲ 32×3 topics
  13. Amyloid Hypothesis9▲ 175×1 topic
  14. Tau Pathology9▲ 175×1 topic
  15. Stress9▲ 23×3 topics
  16. Anxiety9▲ 24×2 topics
  17. Neuropeptides9▲ 81×2 topics
  18. Opioid9▲ 143×1 topic
  19. Receptors9▲ 143×1 topic
  20. Schizophrenia8▲ 64×2 topics
  21. Metabolic Disorders8▲ 41×3 topics
  22. Neuronal Function7▲ 62×2 topics
  23. Amino Acid Transporters7▲ 169×1 topic
  24. D-Serine7▲ 169×1 topic
  25. Cell Signaling7▲ 20×6 topics
  26. Glycemic Control6▲ 42×2 topics
  27. Insulin Therapy6▲ 53×2 topics
  28. Type 2 Diabetes6▲ 31×2 topics
  29. Cardiovascular Outcomes6▲ 135×1 topic
  30. Glucose Control6▲ 135×1 topic
  31. Neurological Disorders5▲ 7.2×5 topics
  32. Protein-Protein Interactions4▲ 39×3 topics
  33. Cancer Progression4▲ 18×3 topics
  34. Glycosylation4▲ 18×3 topics
  35. Immune System3▲ 10×2 topics
  36. Glycans3▲ 38×1 topic
  37. Mucins3▲ 38×1 topic
  38. 14-3-3 Proteins3▲ 324×1 topic
  39. cancer development3▲ 324×1 topic
  40. Transcriptional Regulation3▲ 10×3 topics

Which research topics does Probiodrug (Germany) publish most on?

By volume in 2022-now: CRISPR and Genetic Engineering, Retinal Development and Disorders and Retinal Diseases and Treatments.

CRISPR and Genetic Engin…0CRISPR and Genetic Engineering: 0 fractional worksRetinal Development and …0Retinal Development and Disorders: 0 fractional worksRetinal Diseases and Tre…0Retinal Diseases and Treatments: 0 fractional works
Molecular BiologyOphthalmology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CRISPR and Genetic Engineering Molecular Biology 0 works
  2. 2 Retinal Development and Disorders Molecular Biology 0 works
  3. 3 Retinal Diseases and Treatments Ophthalmology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available33.2%not open66.8%

World: 40% of research is openly available.

with international co-authors32.2%domestic only67.8%

World: 18% is written across borders.

How has Probiodrug (Germany)'s research output changed?

Output in 2022-2025 was 88% lower than in 2018-2021.

200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Probiodrug (Germany) as a percentage of every work published that year, 0.0000039% in 2021.

0.00020%0.00040%0.00060%Probiodrug (Germany)0.0000045% in 2024200020102020

Fractional works of Probiodrug (Germany) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Halle

All research institutions in Halle

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Probiodrug (Germany). Posts are plain text and can be reported.